VistaGen Therapeutics logo
VistaGen Therapeutics VTGN
$ 0.16 -15.79%
report update icon

Quarterly report 2027-Q2
added 11-13-2026

VistaGen Therapeutics Deferred Revenue | VTGN

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.
Features of the metric
  • Sources of future cash inflows
    A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
  • Assessment of operational stability
    Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
  • Risks and obligations
    Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
  • Analysis of liquidity and cash flow
    Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
  • Impact on company valuation
    In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue VistaGen Therapeutics

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999
1.71 M 2.59 M 791 K 714 K 1.24 M 1.42 M - - - - - - - - 13.2 K - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
2.59 M 13.2 K 1.21 M

Quarterly Deferred Revenue VistaGen Therapeutics

2027-Q2 2027-Q1 2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
96 K 234 K 1.71 M 2 M 2.14 M 2.51 M 2.59 M 2.51 M 2.47 M 2.3 M 791 K 1.76 M 793 K 714 K 714 K 793 K 714 K 714 K 1.24 M 712 K 1.24 M 1.24 M 1.42 M 1.42 M 1.42 M 1.42 M 1.24 M 1.24 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
2.59 M 96 K 1.36 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer Deferred Revenue Price % 24h Market Cap Country
Translate Bio, Inc. Translate Bio, Inc.
TBIO
67.6 M - - $ 2.81 B usaUSA
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
541 K - - $ 10.9 B usaUSA
Zogenix, Inc. Zogenix, Inc.
ZGNX
5.32 M - -4.97 % $ 664 M usaUSA
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
6.39 M - -7.58 % $ 264 M usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
9.77 M $ 3.71 -1.72 % $ 1.19 B usaUSA
Vir Biotechnology Vir Biotechnology
VIR
12.6 M $ 8.37 -5.64 % $ 1.16 B usaUSA
Veracyte Veracyte
VCYT
1.16 M $ 25.08 0.16 % $ 1.97 B usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
174 K $ 3.44 -6.27 % $ 203 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
1.59 M $ 1.52 -5.9 % $ 89.2 M usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
782 K $ 2.74 -5.03 % $ 29.2 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
44.4 M $ 2.56 -6.07 % $ 432 M singaporeSingapore
XBiotech XBiotech
XBIT
4.5 M $ 1.75 4.17 % $ 53.4 M usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
35 K $ 1.37 -7.43 % $ 922 M israelIsrael
ADMA Biologics ADMA Biologics
ADMA
143 K $ 13.18 -1.2 % $ 3.14 B usaUSA
Exicure Exicure
XCUR
17.3 M $ 0.96 -7.24 % $ 6.05 M usaUSA
Xencor Xencor
XNCR
30.3 M $ 33.48 -1.56 % $ 2.49 B usaUSA
Daré Bioscience Daré Bioscience
DARE
1 M $ 0.41 -9.93 % $ 4.58 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
381 K $ 0.92 -9.07 % $ 109 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
3.25 M $ 91.28 -1.89 % $ 10.9 B usaUSA
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
31.4 M $ 13.18 -2.04 % $ 11.3 B chinaChina
iBio iBio
IBIO
1.15 M $ 0.83 3.01 % $ 86.4 M usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
2.34 M $ 0.02 -56.5 % $ 219 usaUSA
BioAtla BioAtla
BCAB
19.8 M $ 1.74 0.64 % $ 102 M usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
650 K $ 28.91 -8.89 % $ 1.39 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
14 K $ 13.01 0.74 % $ 1.16 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
2.19 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
275 K - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
517 K - - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
240 K - 1.93 % $ 17.4 M usaUSA
AlloVir AlloVir
ALVR
2.66 M - 4.14 % $ 49.1 M usaUSA